<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895046</url>
  </required_header>
  <id_info>
    <org_study_id>HCRN GI19-414</org_study_id>
    <nct_id>NCT04895046</nct_id>
  </id_info>
  <brief_title>Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma</brief_title>
  <official_title>Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walid Shaib, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, single arm trial, evaluating molecularly selected, immune-based combination therapy&#xD;
      in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the&#xD;
      homologous recombination deficient (HRD) signature.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>4-6 months</time_frame>
    <description>Evaluate PFS of patients who achieved a complete response (CR), partial response (PR) or stable disease (SD). PFS is defined as the date of treatment initiation (C1D1) until the criteria for disease progression is met as defined by RECIST 1.1 or death occurs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>5 years</time_frame>
    <description>ORR is the proportion of all subjects with confirmed PR or CR as the Best Overall Response according to RECIST 1.1, from treatment initiation (C1D1) until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5years</time_frame>
    <description>OS is defined as the period measured from the date of treatment initiation (C1D1) to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>5 years</time_frame>
    <description>DoR is defined as the period measured from the time that RECIST 1.1 criteria are met for complete or partial response (whichever status is recorded first) until the date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since treatment started).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>5 years</time_frame>
    <description>Disease control rate (DCR) is the percentage of subjects with SD, PR, or CR according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse events will be assessed using the National Cancer Institution Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>HRD</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Investigational Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1-4 (cycle length 4 weeks): Niraparib 300 mg taken orally on days 1-21 and Dostarlimab 500 mg intravenously on day 1&#xD;
Cycle 5 and above (cycle length 3 weeks): Niraparib 300 mg taken orally on days 1-21 and 1000 mg intravenously on day 1 of every other cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>300 mg taken orally (all cycles)</description>
    <arm_group_label>Investigational Group</arm_group_label>
    <other_name>Zejula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dostarlimab</intervention_name>
    <description>500 mg (cycles 1-4) intravenously</description>
    <arm_group_label>Investigational Group</arm_group_label>
    <other_name>TSR-042</other_name>
    <other_name>GSK4057190</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dostarlimab</intervention_name>
    <description>1000 mg (cycle 5+) intravenously</description>
    <arm_group_label>Investigational Group</arm_group_label>
    <other_name>GSK4057190</other_name>
    <other_name>TSR-042</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject must meet all of the following applicable inclusion criteria to participate in this&#xD;
        study:&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information prior to registration. NOTE: HIPAA authorization may be included in the&#xD;
             informed consent or obtained separately.&#xD;
&#xD;
          -  Age ≥ 18 years at the time of consent.&#xD;
&#xD;
          -  ECOG Performance Status of 0-1 within 14 days prior to registration.&#xD;
&#xD;
          -  Histological or cytological documentation of metastatic adenocarcinoma of the biliary&#xD;
             tract per AJCC, 8th edition.&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 within 28 days prior to registration.&#xD;
&#xD;
          -  Must have a defined HRD signature (BRCA1, BRCA2, PALB2, MRE, CHEK1, CHEK2, PTEN, ATM,&#xD;
             ATR, BER, RPA1, RAD51, BARD1, BRIP1, FAAP20, FANCM, FAN1, NBN, EMSY, MRE11, ARID1A,&#xD;
             BAP-1.) NOTE: Clinical Laboratory Improvement Act (CLIA)-certified assays including&#xD;
             commercial tests (Foundation Medicine, Caris, Tempus, Guardant 360 or other platforms&#xD;
             of next generation sequencing) will be allowed.&#xD;
&#xD;
          -  Patients should have achieved complete response (CR), partial response (PR) or stable&#xD;
             disease (SD) after 4 to 6 months of platinum-based therapy.&#xD;
&#xD;
          -  No prior treatment with immune therapy, PARP inhibitors or immune checkpoint&#xD;
             inhibitors. Immune therapy defined as any target involving an immune pathway.&#xD;
&#xD;
          -  Prior cancer treatment must be completed at least 14 days prior to registration and&#xD;
             the subject must not have unresolved ≥ Grade 2 toxicity attributed to prior&#xD;
             therapy/procedure. Exceptions include alopecia and oxaliplatin induced neurotoxicity ≤&#xD;
             Grade 2. C1D1 treatment will start no more than 28 days after prior cancer treatment.&#xD;
             Patients that are &gt; 28 days from prior treatment will need to be discussed with the&#xD;
             sponsor-investigator.&#xD;
&#xD;
          -  Life expectancy of ≥ 16 weeks per estimation of site investigator.&#xD;
&#xD;
          -  Demonstrate adequate organ function as defined in the table in the protocol. All&#xD;
             screening labs to be obtained within 7 days prior to registration.&#xD;
&#xD;
          -  Negative urine or serum pregnancy test done ≤ 72 hours prior to C1D1 for women of&#xD;
             childbearing potential.&#xD;
&#xD;
          -  Women of childbearing potential and their partners, who are sexually active, must&#xD;
             agree to the use of TWO highly effective forms of contraception in combination. This&#xD;
             must be started from the time of registration and continue during study treatment and&#xD;
             for at least 120 days (4 months) after last dose of study drug(s), or they must&#xD;
             totally/truly abstain from any form of sexual intercourse. NOTE: Postmenopausal is&#xD;
             defined as: Amenorrheic for 1 year or more following cessation of exogenous hormonal&#xD;
             treatments, Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in&#xD;
             the post-menopausal range for women under 50, Radiation-induced oophorectomy with last&#xD;
             menses &gt; 1 year ago, Chemotherapy-induced menopause with &gt; 1 year interval since last&#xD;
             menses, Surgical sterilization (bilateral oophorectomy or hysterectomy).&#xD;
&#xD;
          -  Male patients must use a condom beginning prior to C1D1 and for 120 days (4 months)&#xD;
             after the last dose of study medications when having sexual intercourse with a&#xD;
             pregnant woman or with a woman of childbearing potential. Female partners of male&#xD;
             patients must also use a highly effective form of contraception if they are of&#xD;
             childbearing potential. Male patients should not donate sperm beginning prior to C1D1&#xD;
             and for 90 days (3 months) following the last dose of study medications.&#xD;
&#xD;
          -  Patients must agree to not donate blood during the study or for 90 days after the last&#xD;
             dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects meeting any of the criteria below may not participate in the study:&#xD;
&#xD;
          -  Patient is simultaneously enrolled in any interventional clinical trial.&#xD;
&#xD;
          -  Tumor embolization ≤ 4 weeks prior to registration.&#xD;
&#xD;
          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism ≤ 6&#xD;
             months prior to registration.&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or any hemorrhage or bleeding event &gt; CTCAE&#xD;
             v5.0 grade 3, ≤ 4 weeks prior to registration.&#xD;
&#xD;
          -  Radiotherapy encompassing &gt; 20% of the bone marrow within 2 weeks prior to&#xD;
             registration. Palliative radiation therapy to a small field &gt;1 week prior to Day 1 of&#xD;
             study treatment may be allowed.&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury ≤ 28 days prior&#xD;
             to registration AND have recovered from surgery.&#xD;
&#xD;
          -  Congestive heart failure - New York Heart Association (NYHA) ≥ Class II.&#xD;
&#xD;
          -  Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible&#xD;
             cardiac conditions, as judged by the investigator (eg. unstable ischemia, uncontrolled&#xD;
             symptomatic arrhythmia, corrected QT interval by Fridericia's correction formula&#xD;
             (QTcF) prolongation &gt; 500 ms), or patients with congenital long QT syndrome. Cardiac&#xD;
             arrhythmias requiring anti-arrhythmic therapy NOTE: Pacemaker, beta blockers or&#xD;
             digoxin are permitted.&#xD;
&#xD;
          -  Ongoing infection &gt; Grade 2 National Cancer Institute (NCI)-Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE) version (v)5.0.&#xD;
&#xD;
          -  Patient taking medications with a known risk to prolong the QTc interval and/or cause&#xD;
             Torsades de Pointes. NOTE: Patients must be discontinued ≥ 7 days of registration.&#xD;
             Treating physicians may wish to replace the drug(s) that do not carry this risk with&#xD;
             safe alternative(s).&#xD;
&#xD;
          -  Uncontrolled hypertension. (Systolic blood pressure &gt; 140 mmHg or diastolic pressure &gt;&#xD;
             90 mmHg despite optimal medical management).&#xD;
&#xD;
          -  Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg]&#xD;
             reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative]&#xD;
             is detected).&#xD;
&#xD;
          -  Patients known to be human immunodeficiency virus (HIV) serologically positive.&#xD;
&#xD;
          -  Seizure disorder requiring medication.&#xD;
&#xD;
          -  Participant has leptomeningeal disease, carcinomatous meningitis, symptomatic brain&#xD;
             metastases, or radiologic signs of CNS hemorrhage. NOTE: Participants with&#xD;
             asymptomatic brain metastases (i.e. off corticosteroids and anticonvulsants for at&#xD;
             least 7 days) are permitted.&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Renal failure requiring hemo-or peritoneal dialysis.&#xD;
&#xD;
          -  Steroid use of &gt; than the equivalence of 5 mg of prednisone.&#xD;
&#xD;
          -  Participant must not have a history of interstitial lung disease.&#xD;
&#xD;
          -  Any autoimmune disease that has required systemic treatment in the past 2 years (ie,&#xD;
             with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).&#xD;
             Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement&#xD;
             therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of&#xD;
             systemic treatment.&#xD;
&#xD;
          -  Participant has a diagnosis of immunodeficiency or has received systemic steroid&#xD;
             therapy or any other form of immunosuppressive therapy within 7 days prior to&#xD;
             initiating protocol therapy.&#xD;
&#xD;
          -  Participant has received a transfusion (platelets or red blood cells) ≤ 4 weeks prior&#xD;
             to initiating protocol therapy.&#xD;
&#xD;
          -  Participant has received colony stimulating factors (e.g., granulocyte&#xD;
             colony-stimulating factor, granulocyte macrophage colony stimulating factor, or&#xD;
             recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.&#xD;
&#xD;
          -  Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due&#xD;
             to prior chemotherapy that persisted &gt; 4 weeks and was related to the most recent&#xD;
             treatment.&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation.&#xD;
&#xD;
          -  Unable to swallow orally administered medications.&#xD;
&#xD;
          -  Any malabsorption condition and/or patients with gastrointestinal disorders likely to&#xD;
             interfere with absorption of the study medication.&#xD;
&#xD;
          -  History of organ allograft including stem cell or cord blood transplantation.&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens. Patients considered a poor medical risk due to a serious,&#xD;
             uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled&#xD;
             infection. Examples include, but are not limited to, uncontrolled ventricular&#xD;
             arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure&#xD;
             disorder, unstable spinal cord compression, superior vena cava syndrome, extensive&#xD;
             interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan&#xD;
             or any psychiatric disorder that prohibits obtaining informed consent.&#xD;
&#xD;
          -  Currently receiving any other investigational agent which would be considered as a&#xD;
             treatment for the primary neoplasm.&#xD;
&#xD;
          -  Participant must not have had diagnosis, detection, or treatment of another type of&#xD;
             cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell&#xD;
             carcinoma of the skin and cervical cancer that has been definitively treated).&#xD;
&#xD;
          -  Myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of&#xD;
             myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).&#xD;
&#xD;
          -  Concurrent use of warfarin or other warfarin-derived anticoagulant. NOTE: Concurrent&#xD;
             use of heparin, direct oral anticoagulants, low molecular weight heparin (LMWH), or&#xD;
             fondaparinux is allowed.&#xD;
&#xD;
          -  Participant taking medications or herbal products including grapefruits, grapefruit&#xD;
             hybrids, pomelos, star fruits, Seville oranges, pomegranates, or the juice from any of&#xD;
             these. NOTE: Patients must discontinue the drug/product ≥ 7 days prior to&#xD;
             registration.&#xD;
&#xD;
          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the&#xD;
             mother is being treated on study).&#xD;
&#xD;
          -  Judgment by the investigator that the patient should not participate in the study if&#xD;
             the patient is unlikely to comply with study procedures, restrictions and&#xD;
             requirements.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walid Shaib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walid Shaib, MD</last_name>
    <phone>404-778-8016</phone>
    <email>walid.labib.shaib@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robyn Lillie</last_name>
    <phone>317-634-5842</phone>
    <phone_ext>60</phone_ext>
    <email>rlillie@hoosiercancer.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nguyen</last_name>
      <phone>404-778-5680</phone>
      <email>kim.t.nguyen@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Walid Shaib, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Walid Shaib, MD</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

